Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-conjugating enzyme E2 K (UBE2K) is an E2 ubiquitin ligase involved in the ubiquitination pathway, specifically the synthesis of Lys48-linked polyubiquitin chains, targeting proteins for proteasomal degradation. It participates in ERAD, DNA damage repair, apoptosis regulation, and other cellular processes. UBE2K interacts with proteins like Huntingtin (HTT) and RNF2. Aberrant UBE2K activity has been implicated in cancer progression and neurodegenerative diseases.
Inhibiting or modulating the ubiquitination process facilitated by UBE2K.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 K (UBE2K).